Since selective BCL-2 inhibition is a promising treatment strategy in hematologic malignancies, the therapeutic impact of venetoclax (formerly known as ABT-199) has been tested in HR-MDS harboring the above mutations. The gene discussed is BCL2; the disease is myelodysplastic syndrome.